QUOTED. Dec 13, 2017. Kyparissia Sirinakis.
Executive Summary
Check out what Kyparissia Sirinakis, managing partner of Epidarex Capital, had to say about misperceptions related to early-stage medtech venture investing.
"There's a bit of a misperception that the exits are not as large. There's also a little bit of a misperception that corporate buyers in the medtech space aren't going to come in very early, they're not going to pay too much, and then you're going to struggle to get reimbursement." – Kyparissia Sirinakis, managing partner, Epidarex Capital
> Find out more: Harpoon Finds Its Whale: Edwards Spends Up To $250m For Beating-Heart Mitral Repair Option
Click here for a free trial of Medtech Insight